Hard capsules C.M.P Forte Ferrer treat peripheral neuropathy (6 blisters x 5 tablets)

Dosage form Box of 6 blisters x 5 tablets
Specifications Cytidin Monophosphate Disodium, Uridin Monophosphate Disodium

Ingredient

Composition informationContent
Cytidin monophosphate disodium5mg
Uridin Monophosphate Disodium3mg

Uses

Indications

c.m.p Forte indicated in the following cases:

  • Treatment of diseases related to peripheral nerve damage with osteoarthritis (sciatica, neuritis, ...); Metabolism (diabetes, alcoholic polythitis, ...); Bacterial infection (Herpes Zoster) and cold weather. (UTP), which is used a lot in the treatment of diseases related to peripheral nerve damage.

    CMP is involved in the synthesis of lipid complexes that make up the nerve cell membrane, especially sphingomyelin, the precursor of myelin bag. CMP is also the precursor of nucleic acids (DNA and RNA), the basic factors in cell metabolism (as in the process of protein synthesis).

    UTP has an act as a coenzym in the process of glycolipid synthesis of nerve structure and myelin bag, supplementing the effects of CMP. In addition, it also has an effect as a substance that provides energy during muscle contraction.

    In short, CMP and UTP are involved in the synthesis of phospholipids and glycolipids that are mainly to form myelin bag and other neurological structures.

    This participation creates a strong metabolic effect to help the Myelin bag regeneration process, which restores myelin bags that have been lost due to peripheral nerve damage. Therefore, the combination of CMP and UTP helps to regenerate myelin bag, restoring the transmission of the streams that are accurate and restoring muscle nutrition.

    Dynamic pharmacokinetics

    These are organic substances found in biological fluids, making the pharmacokinetic studies of the drug more difficult, and that is why the research has been conducted on mice with radioactive isotopes. The objective of this study is to monitor the absorption and pharmacokinetics of UMP, CMP, as well as UTP.

    For this purpose, nucleotids are marked 14C, 14C-ump, 14C-CMP and 14C-UTP are given male mice with single-dose and monitoring the radioactive concentration that appears in the blood and plasma in separate tests.

    In addition, the amount of precursor is determined (UMP, CMP or UTP) and the metabolites in plasma at the selected periods.

    After using 14C-ump at a dose of 4.97 mg/kg, cmax in plasma is achieved after 10 minutes of 1,749 mg/kg. After that, the radioactive substances were quickly eliminated with the half -life of 0.5 and 6.0 hours, respectively for the stage of alpha distribution and deduction of beta.

    After using 14C-CMP at a dose of 4.83 mg/kg, cmax in plasma is achieved after 20 minutes of 1.576 mg/kg. After that, the radioactive substances were quickly eliminated with the selling time of 1.0 and 3.8 hours respectively.

    After using 14C-UTP at a dose of 4.86 mg/kg, cmax in plasma is achieved after 20 minutes of 1,291 mg/kg. After that, the radioactive substances were quickly eliminated with the half -life of 1.2 and 5.0 hours respectively. Similar to 0-72 hours, AUC in plasma of 14C-omp, 14C-CMP and 14C-UTP respectively 6,920 and 10,677 and 7,714 (mg/kg)/hour.

    Compared to plasma, the level of radioactivity found in the blood is almost equivalent or slightly lower and the half -life is similar (0.5 to 1.0 hours) to eliminate radioactive from all three compounds in the Alpha distribution phase (within 2 hours). According to the beta elimination phase, the semi-cancellation time is 8.3 hours (14C-omp) and 8.6 hours (14C-UTP) equivalent to the amount found in plasma.

    Only after using 14C-CMP, during the deduction of beta at 48 hours, blood concentration is about 8 times higher. At 72 hours, the concentration of blood/plasma is similar, this shows that at 48 hours of radioactivity originating from 14C-CMP has temporarily connected to blood cells. Accordingly, the blood in the blood of 14C-CMP reached 5,852 (mg/kg)/hour; of 14C-UTP reached 6.079 (mg/kg)/hour and of 14C-CMP reached 22,144 (mg/kg)/hour.

    After precipitation of the protein, the majority of radioactivity is dissolved and removed and ranges from 57.5% to 90.7%. Only at 48 hours, the amount of UMP and CMP has been removed by 34.0% and 47.0% respectively.

    At 20 minutes after use, no precursor detection (UMP, CMP or UTP) in plasma. For 14C-omp, at least 2 segments of radioactive P2 (Uracil) and P3 (unknown) are found in the amount of 0.338 mg/kg and 0.599 mg/kg respectively.

    After 1 and 2 hours, only P3 is found with the corresponding amounts of 0.273 mg/kg and 0.179 mg/kg respectively.

    For 14C-UTP, 2 radioactive segments are similar to P2 (Uracil) and P3 (unknown) found in the amount of 0.198 mg/kg and 0.288 mg/kg respectively after 20 minutes. After 1 and 2 hours, only P3 is found with 0.265 mg/kg and 0.150 mg/kg respectively.

    For 14C-CMP, the main radioactive segment P1 (cytosin) with the amount of 0.656 mg/kg at 20 minutes and decreased to 0.135 mg/kg and 0.021 mg/kg respectively after 1 and 2 hours. Radioactive segment P2 (Uracil) quantifies 0.263 mg/kg in 20 minutes and decreased slightly to 0.145 mg/kg and 0.124 mg/kg respectively for 1 and 2 hours respectively. Finally, unexplained radioactive segments decreased from 0.308 mg/kg (20 minutes) to 0.137 mg/kg (1 hour) and 0.069 mg/kg (2 hours).

    In short, the transformation of UMP and UTP is similar, rapidly converting through the form of uracil into at least one more polarized radioactive segment.

    CMP compounds are quickly converted to cytosin, uracil and at least one more polarized radioactive segment. Later, cytosin was converted mainly into uracil. This result shows that in uracil blood metabolized worse in the presence of cytosin is the substance created when using CMP at the beginning.

  • Before taking Hard capsules C.M.P Forte Ferrer treat peripheral neuropathy (6 blisters x 5 tablets)

    How to use

    c.m.p Forte hard capsules for oral.

    Dosage

    recommended dose:

  • Adults: 1 - 2 capsules 2 times/day.
  • Children: 1 capsule 2 times/day. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when using overdose?

    What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

  • Side Effects

    Notify the physician the unwanted effects when using the drug.

    Warnings

    Before using the drug you need to read the instructions carefully and refer to the information below.

    contraindicated

    cicado c.m.p forte form contraindicated in the following cases:

  • There is a history of sensitivity to the ingredients of the drug.
  • Caution when using

    No data.

    Drug interaction

    drug interactions may affect the activity of the drug or cause side effects.

    Patients should notify the doctor or pharmacist a list of the drugs and functional foods you are using. Do not use or increase or decrease the dose of the drug without the guidance of a doctor.

    Storage

    Leave a cool place, avoid light, temperature below 30⁰C.

    Other drugs

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    count views

    Popular Keywords